Florida Stem Cell Law SB 1768: 3 Rules Every Patient Should Understand

What Florida Stem Cell Law SB 1768 Is

Florida stem cell law SB 1768 is a state statute enacted to regulate the practice of stem cell therapy by healthcare providers in Florida, establishing specific requirements for informed consent, product disclosure, physician oversight, and advertising practices. The law was passed in response to the rapid growth of stem cell clinics offering treatments that lacked adequate clinical evidence, physician supervision, or transparency about the products being administered. SB 1768 creates a legal framework that protects patients seeking stem cell therapy in Florida while allowing legitimate regenerative medicine providers to continue operating under defined standards.

This article is a plain-language summary. The full regulatory text and compliance framework are covered at the Florida Stem Cell Law SB 1768 resource page.

Rule 1: Physician Supervision Is Required

SB 1768 requires that stem cell therapy be administered under physician supervision. An advanced practice registered nurse (APRN), physician assistant, or other non-physician provider operating independently cannot administer stem cell therapy in Florida without physician oversight. This requirement exists because stem cell products carry biological risks that require the clinical judgment of a licensed physician to manage.

At Rebuild Regen Medical Clinic, [MD_PLACEHOLDER] serves as Medical Director and provides the required physician oversight for all stem cell procedures. Elizabeth Celestin, APRN, FNP-C, conducts intake evaluations and protocol design, but stem cell administration occurs within the physician-supervised framework the law requires.

Rule 2: Informed Consent With Specific Disclosures

SB 1768 mandates specific informed consent disclosures before any stem cell procedure. Patients must be informed that the therapy has not been FDA-approved for the condition being treated, the specific product to be administered including its source and processing standards, known risks and uncertainties associated with the treatment, and that participation is not contingent on a promise of results.

At Rebuild Regen, the consent process covers DayZero™ product specifics, the FDA-registered manufacturing standards of ZEO ScientifiX, the non-approval status of stem cell therapy for most conditions, and the realistic range of outcomes documented in available clinical evidence. Patients sign informed consent before any procedure is scheduled.

Rule 3: Advertising Must Not Misrepresent FDA Status

SB 1768 prohibits Florida stem cell clinics from advertising or marketing stem cell therapy in a way that implies FDA approval, cure claims, or guarantees of outcomes. Clinics that claim their stem cell treatments are FDA-approved are in violation of the law.

Rebuild Regen does not claim FDA approval for stem cell therapy. The DayZero™ products used are manufactured in an FDA-registered cGMP facility, which is a manufacturing standard, not a treatment approval. This distinction is made clearly in all patient communications.

For patients evaluating clinics, SB 1768 compliance is a direct indicator of whether a provider operates with the required transparency and physician oversight. A clinic that cannot produce documentation of its medical director's credentials, biologic product COA, and patient consent disclosures is not compliant with Florida law.

See the stem cell therapy service page for the full protocol at Rebuild Regen and the DayZero stem cell article for product sourcing details.

Is SB 1768 Compliance Something You Should Ask About Before Choosing a Clinic?

SB 1768 compliance is a baseline patient protection requirement, not a differentiator. Every stem cell clinic in Florida is required to comply. The question is whether clinics actually do. Patients are well within their rights to ask any prospective clinic for the name and credentials of their Medical Director, the manufacturer and COA for the biologic product being used, and written consent documentation before any procedure. A clinic that deflects these questions is a significant red flag.

Does SB 1768 Apply Only to Stem Cell Therapy?

SB 1768 is specifically focused on stem cell therapy. PRP, exosome therapy, and peptide therapy have their own regulatory frameworks under existing FDA and state medical practice standards but are not governed by SB 1768's specific disclosure requirements.

When to Seek a Second Opinion Before Proceeding With Stem Cell Therapy

Patients who feel pressured to purchase a stem cell package without adequate clinical evaluation, those whose provider cannot answer specific questions about the biologic product's sourcing and certification, and those for whom a physician has not reviewed their case before the procedure are situations that warrant seeking a second opinion before proceeding.